Begin main content

Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines

Last updated: August 1, 2019
Project Number: RA1056-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of nivolumab, pembrolizumab, or ipilimumab-nivolumab in patients with melanoma who progressed after adjuvant therapy with nivolumab or pembrolizumab?
  2. What is the clinical effectiveness of atezolizumab, nivolumab or pembrolizumab in patients with recurrent/metastatic non-small cell lung cancer (NSCLC) who progressed after consolidation therapy with durvalumab?
  3. What are the evidence-based guidelines on the timing of retreatment with immune checkpoint inhibitors?

Key Message

No relevant clinical evidence was identified regarding the clinical effectiveness of nivolumab, pembrolizumab, or ipilimumab-nivolumab in patients with melanoma who progressed after adjuvant therapy with nivolumab or pembrolizumab. No relevant clinical evidence was identified regarding the clinical effectiveness of atezolizumab, nivolumab or pembrolizumab in patients with recurrent/metastatic non-small cell lung cancer (NSCLC) who progressed after consolidation therapy with durvalumab. Additionally, no relevant evidence-based guidelines were identified regarding the timing of retreatment with immune checkpoint inhibitors.